Volibris Unjoni Ewropea - Daniż - EMA (European Medicines Agency)

volibris

glaxosmithkline (ireland) limited - ambrisentan - hypertension, lunge - antihypertensiva, - volibris is indicated for treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment (see section 5.  efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease. volibris is indicated for treatment of pah in adolescents and children (aged 8 to less than 18 years) of who functional class (fc) ii to iii including use in combination treatment. efficacy has been shown in ipah, familial, corrected congenital and in pah associated with connective tissue disease (see section 5.

Integrilin Unjoni Ewropea - Daniż - EMA (European Medicines Agency)

integrilin

glaxosmithkline (ireland) limited - eptifibatid - angina, unstable; myocardial infarction - antitrombotiske midler - integrilin er beregnet til brug sammen med acetylsalicylsyre og unfractioneret heparin. integrilin er indiceret til forebyggelse af tidlig myokardieinfarkt i patienter med ustabil angina pectoris eller non-q-tak myokardieinfarkt med den sidste episode af brystsmerter, der forekommer inden for 24 timer og med ekg-forandringer og / eller forhøjet hjerte-enzymer. patienter, der er mest tilbøjelige til at drage fordel af integrilin behandling, er dem, der er i høj risiko for udvikling af myokardieinfarkt inden for de første 3-4 dage efter debut af akut angina symptomer, herunder for eksempel dem, der er tilbøjelige til at gennemgå en tidlig perkutan transluminal koronar angioplastik (ptca).

Blenrep Unjoni Ewropea - Daniż - EMA (European Medicines Agency)

blenrep

glaxosmithkline (ireland) limited - belantamab mafodotin - multipelt myelom - antineoplastiske midler - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Ocaliva Unjoni Ewropea - Daniż - EMA (European Medicines Agency)

ocaliva

advanz pharma limited - obeticholic syre - levercirrose, galde - galde og lever terapi - ocaliva er indiceret til behandling af primær biliær cholangitis (også kendt som primær biliær cirrhose) i kombination med ursodeoxycholic syre (udca) hos voksne med et utilstrækkeligt svar til udca eller som monoterapi hos voksne ikke kan tåle udca.

Livmarli Unjoni Ewropea - Daniż - EMA (European Medicines Agency)

livmarli

mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.

Rosuvastatin "Orion" 10 mg filmovertrukne tabletter Danimarka - Daniż - Lægemiddelstyrelsen (Danish Medicines Agency)

rosuvastatin "orion" 10 mg filmovertrukne tabletter

aurobindo pharma (malta) limited - rosuvastatin calcium - filmovertrukne tabletter - 10 mg

Rosuvastatin "Orion" 20 mg filmovertrukne tabletter Danimarka - Daniż - Lægemiddelstyrelsen (Danish Medicines Agency)

rosuvastatin "orion" 20 mg filmovertrukne tabletter

aurobindo pharma (malta) limited - rosuvastatin calcium - filmovertrukne tabletter - 20 mg

Rosuvastatin "Orion" 40 mg filmovertrukne tabletter Danimarka - Daniż - Lægemiddelstyrelsen (Danish Medicines Agency)

rosuvastatin "orion" 40 mg filmovertrukne tabletter

aurobindo pharma (malta) limited - rosuvastatin calcium - filmovertrukne tabletter - 40 mg